<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-129706</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Conjunctival intraepithelial neoplasia. Interferon as a rescue therapy after failure of mitomycin C</dc:title>
<dc:description xml:lang="en">Clinical case: The case of a 60 year-old male with a conjunctival lesion diagnosed as conjunctival intraepithelial neoplasia (CIN), who was treated with mitomycin-C for 3 weeks with minimal improvement. The therapy was change to interferon 2B. Six month later, and after a complete remission of the lesion, the treatment was suspended, with no signs of relapse. Discussion: The treatment of these lesions is currently made with chemotherapy and immunotherapy agents, such as mitomycin-C, 5-fluorouracil, and interferon alfa 2B. The latter, even although is the least used, gives excellent results with fewer secondary effects than mitomycin-C, resulting in an optimal therapy for the non-invasive treatment of CIN lesions (AU)</dc:description>
<dc:creator>Duch-Samper, A</dc:creator>
<dc:creator>Hernández Pérez, D</dc:creator>
<dc:creator>Marí Cotino, J</dc:creator>
<dc:creator>Cruz Aguiló, R.I. de la</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Varón de 60 años con lesión conjuntival diagnosticada de neoplasia intraepitelial corneal conjuntival (NICC), iniciándose tratamiento con mitomicina C. Tras 3 semanas y mínima mejoría, se reemplaza por interferón alfa 2B. Seis meses después, con completa remisión, se suspende el tratamiento sin signos de recidiva. Discusión: Actualmente, el tratamiento de estas lesiones se realiza con agentes quimioterapéuticos o inmunomoduladores como la mitomicina C, el 5-fluorouracilo y el interferón alfa 2B. Este último, a pesar de ser menos utilizado, presenta excelentes resultados con efectos secundarios menores que la mitomicina C, resultando una alternativa óptima para el tratamiento no invasivo de las NICC (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;89(11): 463-465, nov. 2014. ilus</dc:source>
<dc:identifier>ibc-129706</dc:identifier>
<dc:title xml:lang="es">Neoplasia intraepitelial conjuntival. Interferón como terapia de rescate tras fracaso de la mitomicina C</dc:title>
<dc:subject>^d32769</dc:subject>
<dc:subject>^d5236^s22057</dc:subject>
<dc:subject>^d3254^s22057</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d30033^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29961^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201411</dc:date>
</metadata>
</record>
</ibecs-document>
